COVID ‐19 vaccine induced myocarditis in young males: A systematic review
European Journal of Clinical Investigation · 2023-04 · 53 (4)
DOI: 10.1111/eci.13947 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 03.01.2023. Verfasst von Benjamin Knudsen und 1 weiteren Autor:innen. Beteiligte Einrichtung: The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. Hauptthemen laut MEDLINE: Myocarditis, COVID-19. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Background
Myocarditis is a rare but significant adverse event associated with COVID‐19 vaccination, especially for men under 40. If the risk of myocarditis is not stratified by pertinent risk factors, it may be diluted for high‐risk and inflated for low‐risk groups. We sought to assess how the risk of myocarditis is reported in the literature.
Methods
In accordance with PRISMA standards, we reviewed primary publications in PubMed, Embase, Google Scholar and MedRxiv (through 3/2022) and included studies that estimated the incidence of myocarditis/pericarditis after receiving either the BNT162b2 (Pfizer), mRNA‐1273 (Moderna) or Ad26COVS1 (Janssen) vaccine. The main outcome was the percentage of studies using 4, 3, 2, 1 or 0 stratifiers (i.e. sex, age, dose number and manufacturer) when reporting the highest risk of myocarditis. Secondary outcomes included the incidence of myocarditis in males after dose 1 and 2 of the BNT162b2 (Pfizer) or mRNA‐1273 (Moderna) vaccine.
Results
The 29 included studies originated in North America, Europe, Asia, or were Worldwide. Of them, 28% (8/29) used all four stratifiers, and 45% (13/29) used 1 or 0 stratifiers. The highest incidence of myocarditis ranged from 8.1—39 cases per 100,000 persons (or doses) in studies using four stratifiers. Six studies reported an incidence greater than 15 cases per 100,000 persons (or doses) in males aged 12–24 after dose 2 of an mRNA‐based vaccine.
Conclusions
Only one in four articles reporting myocarditis used four stratifiers, and men younger than 40 receiving a second dose of an mRNA vaccine are at greatest risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
- University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Benjamin Knudsen, Vinay Prasad
Förderung
- Arnold Ventures
Zitieren
APA
Knudsen, B., & Prasad, V. (2023). COVID ‐19 vaccine induced myocarditis in young males: A systematic review. European Journal of Clinical Investigation, 53(4). https://doi.org/10.1111/eci.13947
Vancouver
Knudsen B, Prasad V. COVID ‐19 vaccine induced myocarditis in young males: A systematic review. European Journal of Clinical Investigation. 2023;53(4). doi:10.1111/eci.13947
BibTeX
@article{Knudsen2023,
author = {Knudsen, Benjamin and Prasad, Vinay},
title = {COVID ‐19 vaccine induced myocarditis in young males: A systematic review},
journal = {European Journal of Clinical Investigation},
year = {2023},
volume = {53},
number = {4},
doi = {10.1111/eci.13947}
}
EUVIMED